Delavirdine

Generic Name: Delavirdine

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈N_₆O_₃S

CAS Number: 136817-59-9

Unique Ingredient Identifier: DOL5F9JD3E

Overview

A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.

Indication

用于高效抗逆转录病毒疗法（HAART）的组成药物。

Associated Conditions

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir	2014/09/25	NCT02249130	Phase 2	Completed	Boehringer Ingelheim
Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients	2009/01/16	NCT00823966	N/A	Completed	Pfizer
A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy	2001/08/31	NCT00000803	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)
Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects	2001/08/31	NCT00000882	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315	2001/08/31	NCT00000891	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)
A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients	2001/08/31	NCT00002236	Not Applicable	Completed	Pharmacia and Upjohn
A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir	2001/08/31	NCT00000892	Not Applicable	Completed	National Institute of Allergy and Infectious Diseases (NIAID)
A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients	2001/08/31	NCT00001094	Phase 2	Withdrawn	National Institute of Allergy and Infectious Diseases (NIAID)
Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir	2001/08/31	NCT00006326	Not Applicable	Terminated	Agouron Pharmaceuticals
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients	2001/08/31	NCT00002401	Not Applicable	Completed	Pharmacia and Upjohn

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
RESCRIPTOR	viiv healthcare ulc	02238348	Tablet - Oral	100 MG	7/24/1998

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Delavirdine Approved as Second NNRTI for Anti-HIV Combination Therapy

10 months ago

Delavirdine (Rescriptor) received accelerated FDA approval for use in combination with other anti-HIV drugs, marking it as the second NNRTI available for such regimens.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.